🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Small Cell Lung Cancer Limited Stage

To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer NCT07195084NA1 site📍 Hefei Anhui Provincial Cancer Hospital · Tests: Hypervision proton surgery Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer NCT06527898Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: hypofractionated radiotherapy with immunotherapy Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy NCT04829708Phase 32 sites📍 Jinan📍 Jinan Shandong Cancer Hospital and Institute · Tests: MRI Surveillance, Prophylactic Cranial Irradiation Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT NCT05623267Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Sugemalimab, Placebo The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer NCT05502523NA4 sites📍 Abington📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Pulmonary Artery-First Surgical Technique, Biospecimen Collection Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer NCT07008742n/a1 site📍 London Royal Marsden NHS Foundation Trust A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab NCT07391670Phase 119 sites📍 Fitzroy📍 St Albans📍 Woolloongabba AstraZeneca · Tests: SC durvalumab + rHu, IV durvalumab, Tremelimumab Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer NCT07432802NA4 sites📍 Copenhagen📍 Aalborg📍 Aarhus N Aarhus University Hospital · Tests: Stereotactic radiation therapy intervention, Surgical intervention Synapse 3D With Intravascular Indocyanine Green NCT03953144Phase 1, Phase 21 site📍 Hamilton St. Joseph's Healthcare Hamilton · Tests: Synapse 3D Lung Modelling, IC-Green (ICG) MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer NCT05903092Phase 24 sites📍 Indianapolis📍 Iowa City📍 Detroit Hirva Mamdani · Tests: Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer NCT03546829Phase 11 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Vancomycin, Precision hypofractionated radiation Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial NCT07388524Phase 3110 sites📍 Beverly Hills📍 Los Angeles📍 Tarzana National Cancer Institute (NCI) · Tests: Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Ob… Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695Phase 3202 sites📍 Fresno📍 Glendale📍 Orange Boehringer Ingelheim · Tests: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy NCT07010263Phase 353 sites📍 Beijing📍 Beijing📍 Beijing Akeso · Tests: AK112, Placebo Serplulimab Combined With CCRT for LS-SCLC. NCT06295926Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Serplulimab Multiomics Tumor Evolution Model of NSCLC NCT05352035n/a1 site📍 Beijing Peking University People's Hospital Molecular Analysis and Treatment Options of SCLC NCT05945745n/a1 site📍 Shanghai Shanghai Chest Hospital · Tests: Chemotherapy Durvalumab as Consolidation for Patients LS-SCLC NCT07055581Phase 22 sites📍 Zhengzhou📍 Wuhan Qian Chu · Tests: Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced NCT06467383n/a25 sites📍 San Giovanni Rotondo📍 Brescia📍 Campobasso MSD Italia S.r.l. PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: TQB2450, TQB2450 Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06911606Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients NCT07242547Phase 220 sites📍 Albacete📍 Alicante📍 Elche Fundación GECP · Tests: Tarlatamab Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field NCT04944563NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Segmentectomy, Lobectomy Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy NCT07257471n/a1 site📍 Beijing Beijing Haidian Hospital Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06095583Phase 376 sites📍 Harbin📍 Changsha📍 Nanchang Shanghai Junshi Bioscience Co., Ltd. · Tests: Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease NCT07323732Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: BIO 300 Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data NCT07743021n/a33 sites📍 Balatonfüred📍 Békéscsaba📍 Budapest Center for Molecular Fingerprinting Research Nonprofit LLC A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. NCT06284317Phase 342 sites📍 Camperdown📍 Penrith📍 St Leonards ETOP IBCSG Partners Foundation · Tests: Adjuvant durvalumab Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes NCT06699979n/a1 site📍 Changsha Central South University Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer NCT07412327NA1 site📍 Guangzhou Guangzhou Concord Cancer Center · Tests: Stereotactic Body Proton Therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy